Source: Eur Respir J 2012; 39: 805-806
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Wells A.U., Behr J., Costabel U., Cottin V., Poletti V.. Triple therapy in idiopathic pulmonary fibrosis: an alarming press release. Eur Respir J 2012; 39: 805-806

Member's Comments

No comment yet.

Related content which might interest you: Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard Source: Eur Respir J 2015; 45: 1208-1210 Year: 2015 The therapy of idiopathic pulmonary fibrosis: what is next? Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019 Year: 2019 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Exercise training in idiopathic pulmonary fibrosis: is it of benefit? Source: Breathe 2016; 12: 130-138 Year: 2016 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Severe idiopathic pulmonary fibrosis: what can be done? Source: Eur Respir Rev, 26 (145) 170047; 10.1183/16000617.0047-2017 Year: 2017 Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: Comparison with COPD Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions Year: 2013 Pulmonary rehabilitation in idiopathic pulmonary fibrosis: Predictors of adherence and exercise improvement Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation Year: 2013 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Anti-fibrotic role of inhaled interferon-γ in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015